The Effects of Sorafenib on Molecular Barrett's Esophagus Cancer
To determine whether sorafenib is able to change pre-cancerous cells in a way that we believe is important in the progression of cancer.
Esophageal Cancer
DRUG: sorafenib
Ki-67, Biomarker. Change in Ki-67 staining between pre- and on-therapy biopsies in patients with Barrett's esophagus., Two weeks
To characterize the effects of sorafenib on specific molecular markers in patients with Barrett's esophagus and high grade intraepithelial neoplasia (HGIN) or carcinoma in situ (CIS).